Incyte

Yahoo Finance • 9 days ago

Notable healthcare headlines for the week: Apellis, Centessa, and UnitedHealth in focus

Wall Street’s major market averages ended mixed on Thursday as markets assessed President Donald Trump’s address to the nation and the latest developments in the Middle East conflict. The tech-focused Nasdaq Composite finished +0.1%. At t... Full story

Yahoo Finance • 12 days ago

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patientswith and without liver metastases Study will be sponsored and conducted by Incyte; Adagene to provide clinical supply of muzastotug Collaboration p... Full story

Yahoo Finance • 13 days ago

5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up

Quick Read Incyte (INCY) posted FY2025 revenue of $5.14B (+21.2% YoY) with 14 pivotal trials underway across KRASG12D and CDK2 inhibition, while Alnylam (ALNY) achieved first full-year GAAP profitability with FY2025 revenue surging 65.2%... Full story

Yahoo Finance • 13 days ago

Renal Cell Carcinoma Market Report 2026-2030 & 2035: Increasing Immunotherapy and Precision Oncology Programs Drives Market Expansion, Reaching USD 6.09 Billion by 2030

Dublin, April 01, 2026 (GLOBE NEWSWIRE) -- The "Renal Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive analysis, depicting global market size, regional shares,... Full story

Yahoo Finance • 15 days ago

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on market size, reg... Full story

Yahoo Finance • 29 days ago

Qualcomm, Adobe downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Clear Street upgraded Circle Internet(... Full story

Yahoo Finance • 29 days ago

Here Are Monday’s Top Wall Street Analyst Research Calls: Alnylam Pharmaceuticals, Circle Internet, Fifth Third Bancorp, Intuit, ServiceNow, Qualcomm, Trade Desk, and More

Quick Read Stocks closed lower once again on Friday, handing investors their third consecutive week of losses. The “Buy the Dip” investors were rarely wrong using that tactic over the last 3 years, but have been scorched recently While it... Full story

Yahoo Finance • last month

2 Value Stocks to Consider Right Now and 1 We Ignore

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hid... Full story

Yahoo Finance • last month

Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings?

Over the past six months, Incyte has been a great trade, beating the S&P 500 by 8.1%. Its stock price has climbed to $95.88, representing a healthy 11.3% increase. This was partly due to its solid quarterly results, and the run-up might ha... Full story

Yahoo Finance • last month

Incyte fails to win FDA label expansion for cancer therapy due to issues at Novo plant

[FDA headquarters in Washington DC.] JHVEPhoto The U.S. Food and Drug Administration has declined to approve an additional indication for Zynyz, a cancer therapy developed by Incyte (INCY [https://seekingalpha.com/symbol/INCY]) and MacroG... Full story

Yahoo Finance • last month

Assessing Incyte (INCY) Valuation After Recent Share Price Weakness And Mixed Fair Value Signals

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Incyte (INCY) has drawn fresh attention after recent trading left the shares with a 1-day return... Full story

Yahoo Finance • last month

Stock index futures stable after Wall Street selloff; eyes on key labor report

[Wall Street New York City] aluxum/E+ via Getty Images Stock index futures were steady on Friday, a day after Wall Street fell sharply as oil prices surged. Investors are awaiting the key labor report. Dow futures (INDU [https://seekinga... Full story

Yahoo Finance • last month

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology ap... Full story

Yahoo Finance • last month

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 1.3% and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Sector Update: Health Care Stocks Higher Friday Afternoon

Health care stocks rose Friday afternoon, with the NYSE Health Care Index and the State Street Healt PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata

The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS study, in which 42% of patients with severe alopecia areata (AA) reached 80% or more scalp hair coverage at 36 weeks The study is the first and largest of its kind speci... Full story

Yahoo Finance • 2 months ago

Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as... Full story

Yahoo Finance • 2 months ago

Where is Incyte Corporation (INCY) Headed According to Analysts?

Incyte Corporation (NASDAQ:INCY) is one of the best immunotherapy stocks to buy according to hedge funds. Jefferies reiterated a Buy rating on Incyte Corporation (NASDAQ:INCY) on February 11, setting a price target of $120. The same day, M... Full story

Yahoo Finance • 2 months ago

Pharma companies left out of Trump's drug-pricing deals look for way in

By Michael Erman SAN FRANCISCO, Feb 11 (Reuters) - Some pharmaceutical companies not targeted by President Donald Trump for agreements to lower their U.S. drug pricing are looking to craft their own deals in an attempt to avoid potentiall... Full story

Yahoo Finance • 2 months ago

Stocks are Mixed After Weak Retail Sales Data Released

The S&P 500 Index ($SPX) (SPY) today is down -.10%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.12%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.25%. Stock indexes are mixed today. This morning a weaker-than-expected repo... Full story